Prediction of late recurrence and distant metastasis in early-stage breast cancer: Overview of current and emerging biomarkers
Recently, a significant number of breast cancer (BC) patients have been diagnosed at an
early stage. It is therefore critical to accurately predict the risk of recurrence and distant …
early stage. It is therefore critical to accurately predict the risk of recurrence and distant …
The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer
ASA Al-Zawi - Medical Research Journal, 2021 - journals.viamedica.pl
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
[HTML][HTML] How Canadian oncologists use oncotype DX for treatment of breast cancer patients
X Zhu, S Dent, L Paquet, T Zhang, D Tesolin… - Current …, 2021 - mdpi.com
Background: The literature suggests that medical oncologists differ on how they use the
Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast …
Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast …
[HTML][HTML] Probability of a high recurrence score for breast cancer on the Oncotype DX test in males: a case series
REAR da Costa, FTR de Oliveira, CA dos Reis… - Case …, 2023 - revistas.unal.edu.co
Introduction: Male breast cancer (MBC) is a rare disease that accounts for 1% of breast
cancers. The Oncotype DX test (a genomic signature that assesses the expression of 21 …
cancers. The Oncotype DX test (a genomic signature that assesses the expression of 21 …
The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer.
AS Abdalla Al-Zawi - Medical Research Journal (2451-2591), 2021 - search.ebscohost.com
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
positive, human epidermal growth factor receptor-2 negative, lymph-node negative early …
[HTML][HTML] Modernizing the Diagnosis of Male Breast Cancer
G Mauro - letlifehappen.com
Unfortunately, this is a silent statement often internalized by men with breast cancer.
Although the majority of the patient population is made up of women, males represent 1 in …
Although the majority of the patient population is made up of women, males represent 1 in …